ArticleBMC cancer2026
Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of androgen receptor pathway inhibitors (ARPIs), such as abiraterone and enzalutamide, in combination with androgen deprivation therapy (ADT), has significantly enhanced outcomes in metastatic castration-sensitive prostate cancer (mCSPC). However, validated early prognostic markers to guide treatment decisions are still limited. The PSA Kinetic Ratio, a simplified kinetic model based on PSA kinetics, may provide a practical method for early risk assessment.
methodsWe conducted a retrospective study of 146 high-volume mCSPC patients treated with abiraterone or enzalutamide plus ADT. The PSA Kinetic Ratio, calculated from three PSA measurements within the first 100 days of therapy (PSA₃/PSA₁), was used to classify patients into favorable (< 1) or unfavorable (≥ 1) PSA kinetics. The primary endpoint was progression-free survival (PFS). Kaplan-Meier and Cox regression analyses were employed to assess the relationships between the PSA Kinetic Ratio, treatment type, and survival outcomes.
resultsPatients with favorable PSA Kinetic Ratio (PSA Kinetic Ratio <1) experienced significantly longer median PFS compared to those with unfavorable PSA kinetics in both treatment groups (log-rank p < 0.001). Multivariate Cox analysis confirmed that unfavorable PSA kinetics (PSA Kinetic Ratio ≥1) were independently associated with shorter PFS (HR = 2.10; 95% CI: 1.45-3.05; p < 0.001). No significant difference in PFS was observed between abiraterone and enzalutamide within each PSA Kinetic Ratio subgroup.
conclusionThe PSA Kinetic Ratio seems to be a promising and practical prognostic biomarker in high-volume mCSPC. Early PSA decline (Kelim < 1) correlates with better outcomes, regardless of ARPI type. Incorporating it into clinical decision-making may allow for timely treatment adjustments. Prospective validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.